Clene Inc. (NASDAQ:CLNN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Clene Inc. (NASDAQ:CLNN) have earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $34.00.

CLNN has been the topic of several recent research reports. Weiss Ratings lowered Clene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. D. Boral Capital reissued a “buy” rating and issued a $23.00 price objective on shares of Clene in a research note on Thursday, March 12th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $48.00 price objective on shares of Clene in a research note on Friday, March 13th.

Clene Stock Performance

Shares of NASDAQ:CLNN opened at $6.14 on Friday. The business’s 50 day simple moving average is $5.68 and its two-hundred day simple moving average is $6.48. The firm has a market cap of $72.33 million, a P/E ratio of -2.36 and a beta of 0.89. Clene has a 52-week low of $2.28 and a 52-week high of $13.50.

Clene (NASDAQ:CLNN) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million. On average, equities analysts forecast that Clene will post -1.99 earnings per share for the current fiscal year.

Insider Activity at Clene

In other news, major shareholder Chidozie Ugwumba sold 5,736 shares of the stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $6.08, for a total value of $34,874.88. Following the completion of the sale, the insider directly owned 277,569 shares of the company’s stock, valued at $1,687,619.52. This represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 162,884 shares of company stock valued at $947,056 over the last three months. Corporate insiders own 28.30% of the company’s stock.

Institutional Trading of Clene

Several institutional investors and hedge funds have recently modified their holdings of CLNN. SymBiosis Capital Partners LLC purchased a new stake in shares of Clene in the fourth quarter worth approximately $4,523,000. Scoggin Management LP raised its stake in shares of Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after purchasing an additional 107,250 shares during the last quarter. Ensign Peak Advisors Inc raised its stake in shares of Clene by 668.6% in the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock worth $671,000 after purchasing an additional 99,481 shares during the last quarter. PEAK6 LLC purchased a new stake in shares of Clene in the fourth quarter worth approximately $294,000. Finally, State Street Corp raised its stake in shares of Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after purchasing an additional 17,300 shares during the last quarter. 23.28% of the stock is owned by hedge funds and other institutional investors.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).